Sign in
Not yet taking people in NetherlandsPhase 2

Tests axitinib and avelumab before surgery for kidney cancer

Tests two drugs, axitinib and avelumab, before surgery in adults with kidney cancer.

Key facts

Who runs it
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Where
Amsterdam, NetherlandsSee the site
Registry title
Neoadjuvant AXITINIB plus AVELUMAB for patients with localized RCC and a moderate to high risk of recurrence
Status
Not yet recruiting
Phase
Phase 2
People taking part
40 people, planned
Started
25 Sept 2017
Expected to end
31 Oct 2031
Type of study
Interventional
Record updated
11 July 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with kidney cancer (clear-cell type) that has not spread and has a moderate to high risk of coming back. The tumour must be fully removable by surgery.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Clear-cell renal cell carcinoma that has not spread (cM0), with moderate to high risk of recurrence based on clinical tumour stage and biopsy grade. The main tumour must be fully removable by surgery. WHO performance status 0-1.
Earlier treatment
No chemotherapy, immunotherapy, biologic, hormonal or investigational cancer treatment within 14 days or five half-lives of a drug (whichever is longer) before the first dose. No non-cancer investigational drug within 30 days or 5 half-lives (whichever is longer).

Main reasons for not taking part

  • Low-risk kidney tumour or non-clear-cell type on biopsy
  • Cancer that has spread to other organs (M1)
  • Past organ transplant, including stem cell transplant
  • HIV, active hepatitis B or hepatitis C infection
  • Pregnancy or breastfeeding

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Male or female patients age ≥ 18 years
  • Highly effective contraception for both male and female subjects if the risk of conception exists
  • Signed and written informed consent
  • Histologically confirmed diagnosis of non-metastatic clear-cell renal cell carcinoma of intermediate to high risk with completely resectable primary tumours. For the purpose of this study intermediate to high risk will be based on clinical TNM and biopsy nuclear grade since the full pathological specimen is not available. These are: • cT1b-cT2a grade 4 cN0 cM0 • cT2b grade 3 cN0 cM0 • cT3a grade 3-4 cN0 cM0 • cT3b-cT4 any grade cN0 cM0 • cT any cN1 (fully resectable) cM0
  • World Health Organization (WHO) performance status of 0-1
  • Adequate coagulation function
  • Adequate hematological function defined by absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L, and hemoglobin ≥ 5,6 mmol/L (may have been transfused)
  • Adequate hepatic function defined by a total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range and AST and ALT levels ≤ 2.5 × ULN for all subjects
  • Adequate renal function defined by an estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula
  • Negative serum pregnancy test at screening for women of childbearing potential

Who cannot take part

  • Treatment with any of the following anti-cancer therapies:  chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of axitinib or avelumab
  • Administration of any non-oncologic investigational drug within 30 days or 5 half lives whichever is longer prior to receiving the first dose of study treatment
  • Prior organ transplantation, including allogeneic stem cell transplantation
  • Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent
  • Known alcohol or drug abuse
  • Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
  • Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:  Malabsorption syndrome  Major resection of the stomach or small bowel
  • Major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery)
  • Evidence of active bleeding or bleeding diathesis
  • Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject’s safety, provision of informed consent, or compliance to study procedures
  • Significant acute or chronic infections including, among others: Known history of testing positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) Positive test for HBV surface antigen and / or confirmatory HCV RNA (if anti-HCV antibody tested positive)
  • Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 NCI CTCAE v 4.03), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
  • Metastatic disease, M1
  • All other significant diseases (for example, inflammatory bowel disease, uncontrolled asthma), which, in the opinion of the Investigator, might impair the subject’s tolerance of trial treatment
  • Any psychiatric condition that would prohibit the understanding or rendering of informed consent
  • History of any one or more of the following cardiovascular conditions within the past 6 months:  Cardiac angioplasty or stenting  Myocardial infarction  Unstable angina  Coronary artery bypass graft surgery  Symptomatic peripheral vascular disease  Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)
  • Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥140 mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg]
  • History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months
  • Corrected QT interval (QTc) > 480 msecs
  • Renal tumors of low risk
  • Pregnancy or lactation
  • Non-clear cell histology at biopsy

Where in Netherlands

  • Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, NetherlandsNot yet recruiting

About the trial

What the trial wants to find out

To investigate efficacy of neoadjuvant axitinib and avelumab in patients with localized renal cell carcinoma with moderate to high risk of recurrence

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Neoadjuvant AXITINIB plus AVELUMAB for patients with localized RCC and a moderate to high risk of recurrence (N17JAV)
Plain-language title
Tests axitinib and avelumab before surgery for kidney cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
11 July 2024